{"id":"NCT04127786","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults","officialTitle":"Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free in Comparison With Verorab® and Imovax® Rabies, in a Pre-exposure Regimen in Both Pediatric and Adult Populations and a Single Booster Dose of Purified Vero Rabies Vaccine - Serum Free Administered at 1 Year Post-3-dose Primary Series, and Between 2 up to 3 Years Post-One Week 2-Dose Primary Series in a Subset of Adults in Thailand","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-21","primaryCompletion":"2020-03-25","completion":"2025-04-24","firstPosted":"2019-10-16","resultsPosted":"2024-02-09","lastUpdate":"2025-07-04"},"enrollment":1708,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Rabies","Healthy Volunteers"],"interventions":[{"type":"BIOLOGICAL","name":"Purified vero rabies vaccine - serum free - VRVg-2","otherNames":[]},{"type":"BIOLOGICAL","name":"Purified inactivated rabies vaccine - Verorab®","otherNames":[]},{"type":"BIOLOGICAL","name":"Purified inactivated rabies vaccine - Imovax® Rabies","otherNames":[]}],"arms":[{"label":"Group1:VRVg2 Cohort1(C1)-1ry Series:pediatric&adult participants-Booster:102 adult participants","type":"EXPERIMENTAL"},{"label":"Group 2:Verorab C1-1ry Series:pediatric&adult participants-Booster Phase:34 adult participants","type":"ACTIVE_COMPARATOR"},{"label":"Group 3:Imovax Rabies C1-1ry Series:pediatric&adult participants-Booster Phase:34 adult participants","type":"ACTIVE_COMPARATOR"},{"label":"Group 4:VRVg-2 Cohort 2(C2)-1ry Series:Adult participants-Booster Phase:138 adult participants","type":"EXPERIMENTAL"},{"label":"Group 5:Verorab C2-1ry Series:adult participants-Booster Phase:46 adult participants","type":"ACTIVE_COMPARATOR"},{"label":"Group 6:Imovax Rabies C2-1ry Series:adult participants-Booster Phase:46 adult participants","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is:\n\nTo demonstrate the VRVg-2 is non-inferior to Verorab and Imovax Rabies vaccines in each age group (pediatric and adult populations) when administered as a 3-dose PrEP regimen, in terms of proportion of participants achieving a rabies virus neutralizing antibody (RVNA) titer ≥ 0.5 IU/mL at Day 42, ie. 14 days after the 3rd injection (for Primary Series Cohort 1).\n\nThe secondary objectives of this study are: First 1-5 with hypotheses testing will be evaluated sequentially - only if the previous objective is achieved, will the next objective be tested\n\nTo demonstrate that:\n\n* the observed proportion of participants in the VRVg2(VRVg) group at D42 is at least 99% with a lower limit of the 95% confidence interval (CI) of at least 97%\n* VRVg is non inferior (NI) to Verorab and Imovax Rabies vaccines (Imovax) in each age group at D28\n* 2-dose VRVg at D28 is NI to 3-dose Imovax at D42 in each age group\n* the observed proportion of participants in the VRVg group at D28 is at least 99% with a lower limit of the 95% CI of at least 97%\n* 2-dose Imovax at D28 is NI to 3-dose Imovax at D42 in overall participants (Cohort1)\n\nTo describe:\n\n* the immune response induced by VRVg versus Verorab and Imovax at D28 and at D42 in all age groups\n* the immune response induced by VRVg at D14 after a booster dose of VRVg administered at M12 (Cohort1) and between M24 up to M36 (Cohort2)\n* the persistence of immune response at M6,12,18, and pre-booster between M24 up to M36 post-primary series vaccination (Cohort2)\n* safety profile of VRVg versus Verorab and Imovax in primary series and after a booster dose of VRVg","primaryOutcome":{"measure":"Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titer Greater Than or Equal to (>=) 0.5 IU/mL","timeFrame":"Day 42 (post-vaccination)","effectByArm":[{"arm":"Primary Series: Cohort-1 Group 1: VRVg-2","deltaMin":100,"sd":null},{"arm":"Primary Series: Cohort-1 Group 2: Verorab®","deltaMin":100,"sd":null},{"arm":"Primary Series: Cohort-1 Group 3: Imovax Rabies®","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":4,"countries":["Thailand"]},"refs":{"pmids":["39587931"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":607},"commonTop":["Injection Site Pain","Myalgia","Malaise","Headache","Pyrexia"]}}